
Cahill Represents Lead Arrangers in \$600 Million Credit Facilities for Halozyme Therapeutics, Inc.

Date: 05/24/22

Cahill represented the Lead Arrangers in connection with a \$250,000,000 term A credit facility and a \$350,000,000 revolving credit facility for Halozyme Therapeutics, Inc. Proceeds from the credit facilities, together with cash on hand, were used to fund Halozyme Therapeutics, Inc.'s acquisition of Antares Pharma, Inc. and to refinance existing debt. Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes.

Attorney

- Elizabeth Yahl